SureTrader Advertisement
Home > Boards > US OTC > Medical - Drugs > Cellceutix Corporation (CTIX)

Cellceutix has stated several times that there isn't

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
KarinCA Member Profile
Member Level 
Followed By 504
Posts 21,423
Boards Moderated 2
Alias Born 11/16/07
160x600 placeholder
KarinCA Member Level  Sunday, 12/23/12 12:54:34 PM
Re: Gratefullife post# 15360
Post # of 153124 
Cellceutix has stated several times that there isn't competition to their drug kevetrin. Several companies have been working on it, but, none have achieved the same results. Kevetrin works on both the mutated and wild type p53. The competition seems to only work on the wild form. Kevetrin will end up working on many more cancers since it works on the mutated form.

Kevetrin is an HDAC-2 and HDAC-6 regulators. HDM2 is an inhibitor.

Kevetrin has several other subordinate activities, such as, regulating c-myc activity, inducing apoptosis, etc.. It has also been seen that Kevetrin has anti-angiogenic properties.

See my earlier post including info from company: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82597857

See progressive post of earlier PR dealing with this: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82732988

Also, see search of FDA website for the other companies trials and you will notice HDM2 isn't listed yet.
http://www.clinicaltrial.gov/ct2/results?term=Ascenta+Therapeutics%2C+Inc&Search=Search



KarinCAtrades.com

GLTA... KarinCA ;)

"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist